{
    "ticker": "TSLR",
    "name": "Tiziana Life Sciences PLC",
    "description": "Tiziana Life Sciences PLC is a biotechnology company focused on the development of innovative therapies for the treatment of cancer and autoimmune diseases. Founded in 2013 and headquartered in London, UK, Tiziana aims to advance the science of immunotherapy through its proprietary technologies. The company is recognized for its leading drug candidates, including Foralumab, a fully human anti-CD3 monoclonal antibody, designed for the treatment of various autoimmune conditions and potentially for cancer indications. Tiziana is also developing TZL-101, a novel drug that targets specific pathways in the immune system to enhance treatment efficacy. With a strong commitment to scientific research, Tiziana collaborates with leading research institutions and seeks to bring transformative treatments to patients who are in need of novel therapeutic options. The company is driven by the mission to improve the quality of life for patients through innovative and effective therapies, leveraging cutting-edge science and technology in the field of life sciences.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "London, United Kingdom",
    "founded": "2013",
    "website": "https://www.tizianalifesciences.com",
    "ceo": "Dr. Kunwar Shailubhai",
    "social_media": {
        "twitter": "https://twitter.com/TizianaLife",
        "linkedin": "https://www.linkedin.com/company/tiziana-life-sciences/"
    },
    "investor_relations": "https://www.tizianalifesciences.com/investors",
    "key_executives": [
        {
            "name": "Dr. Kunwar Shailubhai",
            "position": "CEO"
        },
        {
            "name": "Dr. Michael E. Nestor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Candidates",
            "products": [
                "Foralumab",
                "TZL-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Tiziana Life Sciences PLC | Innovative Biotechnology Solutions",
        "meta_description": "Learn about Tiziana Life Sciences, a biotechnology company dedicated to developing innovative therapies for cancer and autoimmune diseases. Explore our leading drug candidates and commitment to patient care.",
        "keywords": [
            "Tiziana Life Sciences",
            "Biotechnology",
            "Pharmaceuticals",
            "Immunotherapy",
            "Cancer Treatment",
            "Autoimmune Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Tiziana Life Sciences known for?",
            "answer": "Tiziana Life Sciences is known for developing innovative therapies for cancer and autoimmune diseases."
        },
        {
            "question": "Who is the CEO of Tiziana Life Sciences?",
            "answer": "Dr. Kunwar Shailubhai is the CEO of Tiziana Life Sciences PLC."
        },
        {
            "question": "Where is Tiziana Life Sciences headquartered?",
            "answer": "Tiziana Life Sciences is headquartered in London, United Kingdom."
        },
        {
            "question": "What are Tiziana's main products?",
            "answer": "Tiziana's main products include Foralumab and TZL-101."
        },
        {
            "question": "When was Tiziana Life Sciences founded?",
            "answer": "Tiziana Life Sciences was founded in 2013."
        }
    ],
    "competitors": [
        "AMGN",
        "GILD",
        "BMY",
        "REGN"
    ],
    "related_stocks": [
        "NVAX",
        "AXGN",
        "MDGL",
        "BPMC"
    ]
}